<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Development of99m Tc-EC-tyrosine for Early Detection of Breast Cancer Tumor Response to the Anticancer Drug Melphalan" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/development-of99m-tc-ec-tyrosine-for-early-detection-of-breast-cancer-tumor-response-to-the-anticanc/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/development-of99m-tc-ec-tyrosine-for-early-detection-of-breast-cancer-tumor-response-to-the-anticanc/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2012-12-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Development of99m Tc-EC-tyrosine for Early Detection of Breast Cancer Tumor Response to the Anticancer Drug Melphalan" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T02:43:55+00:00","datePublished":"2012-12-31T17:00:00+00:00","description":"Rationale and Objectives","headline":"Development of99m Tc-EC-tyrosine for Early Detection of Breast Cancer Tumor Response to the Anticancer Drug Melphalan","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/development-of99m-tc-ec-tyrosine-for-early-detection-of-breast-cancer-tumor-response-to-the-anticanc/"},"url":"https://clinicaltree.github.io/posts/development-of99m-tc-ec-tyrosine-for-early-detection-of-breast-cancer-tumor-response-to-the-anticanc/"}</script><title>Development of99m Tc-EC-tyrosine for Early Detection of Breast Cancer Tumor Response to the Anticancer Drug Melphalan | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Development of99m Tc-EC-tyrosine for Early Detection of Breast Cancer Tumor Response to the Anticancer Drug Melphalan</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Development of99m Tc-EC-tyrosine for Early Detection of Breast Cancer Tumor Response to the Anticancer Drug Melphalan</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1356973200" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Dec 31, 2012 </em> </span> <span> Updated <em class="" data-ts="1681094635" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Fan-Lin Kong PhD</a> </em>, <em> <a href="">YinHan Zhang PhD</a> </em>, <em> <a href="">Daniel P. Young MD</a> </em>, <em> <a href="">Dong-Fang Yu PhamD</a> </em>, <em> <a href="">David J. Yang PhD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="2000 words"> <em>11 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Radiolabeled tyrosine analogues that have been successfully used in tumor imaging accumulate in tumor cells via an upregulated L-type amino acid transporter system. The anticancer drug melphalan is an L-type amino acid transporter substrate. Therefore, radiolabeled tyrosine analogues may have great potential in evaluating treatment responses to melphalan. In this study, a 99m Tc-labeled tyrosine analogue, 99m Tc tyrosine using N,N′-ethylene-di-L-cysteine (EC) as a chelator, was developed and its potential for noninvasively assessing tumors’ early response to melphalan determined.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>EC-tyrosine was synthesized in a three-step procedure and labeled with 99m Tc. To assess cellular uptake kinetics, the percentage uptake of 99m Tc-EC-tyrosine in the rat breast cancer cell line 13762 was measured. Planar imaging was performed in rats with 13762 cell-derived tumors. To determine the transport mechanisms of 99m Tc-EC-tyrosine, a competitive inhibition study using L-tyrosine as an inhibitor was performed in vitro and in vivo. To assess tumors’ response to melphalan, tumor-bearing rats were treated with different doses of melphalan, and planar imaging was performed 0 and 3 days after treatment. Immunohistochemical analyses were conducted to determine expressions of L-type amino acid transporter 1 and cellular proliferation marker Ki-67.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>L-tyrosine significantly inhibited 99m Tc-EC-tyrosine uptake in vitro and in vivo. Tumor volume decreased in a dose-dependent manner with melphalan, and tumor/muscle ratios of 99m Tc-EC-tyrosine were significantly reduced in treated groups. Immunohistochemical data indicated that about 70% of tumor cells in the melphalan-treated groups underwent apoptosis, and the changes in tumor/muscle ratios reflected the decreased percentage of viable cells in treated tumors.</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>These findings suggest that 99m Tc-EC-tyrosine has great potential for monitoring tumor response to melphalan in breast tumor–bearing rats.</p><p>Currently, 18 F-2-fluoro-2-deoxy-glucose ( 18 F-FDG) is the most commonly used radiotracer in positron emission tomography (PET) for tumor detection and staging. However, it has several limitations that can give rise to false-positive and false-negative diagnoses. For instance, it has poor contrast in brain tumors because of the high glucose uptake in normal and neoplastic brain tissues . For breast cancer, whole-body 18 F-FDG PET is not quite suitable for primary breast cancer diagnosis, especially for low-grade tumors and those &lt;1 cm in diameter . In addition, 18 F-FDG PET is not sensitive enough in detecting early-stage micrometastases and small tumor–infiltrated axillary lymph nodes .</p><p>Therefore, radiolabeled amino acids have been developed as alternatives to 18 F-FDG. Their application in tumor detection is based on the increased uptake of amino acids in tumor cells, which is presumed to reflect enhanced amino acid transporter expression, metabolism, and protein synthesis. The uptake of amino acids in macrophages and other inflammatory cells is lower than that of glucose analogue 18 F-FDG; thus, amino acid–based radiotracers are considered more specific than 18 F-FDG . Aromatic radiolabeled amino acids such as tyrosine and its derivatives are more suitable given their more readily chemical modifications and more favorable biologic characterizations. To date, tyrosine and its α-methyl-substituted analogue α-methyl tyrosine (AMT) have been successfully labeled with 11 C, 18 F, and 124/125 I for PET and with 123/131 I for single-photon emission computed tomography (SPECT) . Most of these radiolabeled tyrosine analogues have shown promising preclinical and clinical results, particularly in brain tumor staging. They have also been successfully applied to breast cancer imaging. For instance, 11 C-labeled tyrosine appears to be better than 18 F-FDG because of its lower uptake in noncancerous fibrocystic disease . Radiolabeled tyrosine analogues have been found to accumulate in tumor cells, predominantly via the L-type amino acid transporter (LAT) system, which is the only system that can transport large neutral amino acids with aromatic rings . LAT, especially its subtype LAT1, is an ideal target for tumor imaging because it is upregulated and highly expressed in many cancer cell lines, and its expression is positively correlated with tumor growth . In fact, LAT1 has been determined as a prognostic factor in patients with breast cancer, even in those with triple-negative breast cancer .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="chemicals-and-analysis"><span class="mr-2">Chemicals and Analysis</span><a href="#chemicals-and-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="synthesis-of-precursor-ec-tyrosine"><span class="mr-2">Synthesis of Precursor EC-tyrosine</span><a href="#synthesis-of-precursor-ec-tyrosine" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="n-t-butoxycarbonyl-o-3-br-propyl-l-tyrosine-methyl-ester-compound-1"><span class="mr-2">N-t-butoxycarbonyl-O-[3-Br-propyl]-L-tyrosine methyl ester (compound 1)</span><a href="#n-t-butoxycarbonyl-o-3-br-propyl-l-tyrosine-methyl-ester-compound-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="n-t-butoxycarbonyl-o-3-n-ethylenedicysteine-propyl-l-tyrosine-compound-2"><span class="mr-2">N-t-butoxycarbonyl-O-[3-(N-ethylenedicysteine) propyl]-L-tyrosine (compound 2)</span><a href="#n-t-butoxycarbonyl-o-3-n-ethylenedicysteine-propyl-l-tyrosine-compound-2" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="o-3-n-ethylenedicysteine-propyl-l-tyrosine-ec-tyrosine-compound-3"><span class="mr-2">O-[3-(N-ethylenedicysteine) propyl]-L-tyrosine (EC-tyrosine) (compound 3)</span><a href="#o-3-n-ethylenedicysteine-propyl-l-tyrosine-ec-tyrosine-compound-3" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="radiolabeling-ec-tyrosine-and-ec-with--99m--tc"><span class="mr-2">Radiolabeling EC-tyrosine and EC with 99m Tc</span><a href="#radiolabeling-ec-tyrosine-and-ec-with--99m--tc" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="determination-of-the-partition-coefficient"><span class="mr-2">Determination of the Partition Coefficient</span><a href="#determination-of-the-partition-coefficient" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="invitro-cellular-uptake-studies"><span class="mr-2">In Vitro Cellular Uptake Studies</span><a href="#invitro-cellular-uptake-studies" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="invitro-competitive-inhibition-study"><span class="mr-2">In Vitro Competitive Inhibition Study</span><a href="#invitro-competitive-inhibition-study" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="blood-clearance"><span class="mr-2">Blood Clearance</span><a href="#blood-clearance" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="invivo-tissue-distribution-study-of--99m--tc-ec-tyrosine"><span class="mr-2">In Vivo Tissue Distribution Study of 99m Tc-EC-tyrosine</span><a href="#invivo-tissue-distribution-study-of--99m--tc-ec-tyrosine" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="planar-scintigraphic-imaging-study"><span class="mr-2">Planar Scintigraphic Imaging Study</span><a href="#planar-scintigraphic-imaging-study" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="invivo-uptake-blocking-study"><span class="mr-2">In Vivo Uptake Blocking Study</span><a href="#invivo-uptake-blocking-study" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="melphalan-treatment-response-assessment"><span class="mr-2">Melphalan Treatment Response Assessment</span><a href="#melphalan-treatment-response-assessment" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="chemical-and-radiochemical-characteristics"><span class="mr-2">Chemical and Radiochemical Characteristics</span><a href="#chemical-and-radiochemical-characteristics" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/0_1s20S1076633212004230.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/0_1s20S1076633212004230.jpg" alt="Figure 1, Synthetic scheme of precursor EC-tyrosine. EC, N,N′-ethylene-di-L-cysteine." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="invitro-cellular-uptake-studies-1"><span class="mr-2">In Vitro Cellular Uptake Studies</span><a href="#invitro-cellular-uptake-studies-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/1_1s20S1076633212004230.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/1_1s20S1076633212004230.jpg" alt="Figure 2, Time course of 99m Tc-EC-tyrosine and 99m Tc-EC uptake in the rat breast tumor cell line 13762 (0–240 minutes). Data are expressed as mean percentage uptake ± standard deviation. EC, N,N′-ethylene-di-L-cysteine." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="competitive-inhibition-study-of--99m--tc-ec-tyrosine"><span class="mr-2">Competitive Inhibition Study of 99m Tc-EC-tyrosine</span><a href="#competitive-inhibition-study-of--99m--tc-ec-tyrosine" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/2_1s20S1076633212004230.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/2_1s20S1076633212004230.jpg" alt="Figure 3, Competitive inhibition uptake of 99m Tc-EC-tyrosine by L-tyrosine in the rat breast tumor cell line 13762 for up to 60 minutes. Three concentrations of L-tyrosine (10× to 100× EC-tyrosine concentration [8 mg/well]) were used. Data are expressed as mean percentage uptake ± standard deviation. EC, N,N′-ethylene-di-L-cysteine. ∗ P &lt; .05 compared to the control group." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="blood-clearance-1"><span class="mr-2">Blood Clearance</span><a href="#blood-clearance-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/3_1s20S1076633212004230.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/3_1s20S1076633212004230.jpg" alt="Figure 4, Blood clearance (percentage of the injected dose per gram of blood [%ID/g]) of 99m Tc-EC-tyrosine in normal female Fischer 344 rats. Data represent mean radioactivity expressed as a %ID/g ± standard deviation ( n = 9/time point). EC, N,N′-ethylene-di-L-cysteine." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="invivo-tissue-distribution-of--99m--tc-ec-tyrosine"><span class="mr-2">In Vivo Tissue Distribution of 99m Tc-EC-tyrosine</span><a href="#invivo-tissue-distribution-of--99m--tc-ec-tyrosine" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Tissue Distribution Results for 99m Tc-EC-tyrosine in Normal Fischer 344 Rats</p><p>Organ Time Point (minutes) 30 120 240 Blood 0.96 ± 0.076 0.41 ± 0.039 0.23 ± 0.006 Heart 0.24 ± 0.007 0.12 ± 0.011 0.08 ± 0.009 Lungs 0.47 ± 0.041 0.33 ± 0.001 0.20 ± 0.025 Thyroid 0.43 ± 0.036 0.24 ± 0.001 0.11 ± 0.002 Pancreas 0.21 ± 0.018 0.17 ± 0.016 0.10 ± 0.007 Liver 1.47 ± 0.045 2.42 ± 0.075 0.97 ± 0.007 Spleen 0.47 ± 0.054 1.41 ± 0.117 0.62 ± 0.036 Kidneys 11.12 ± 0.545 16.50 ± 0.395 11.13 ± 0.234 Stomach 0.27 ± 0.006 0.19 ± 0.002 0.08 ± 0.000 Intestine 1.13 ± 0.009 0.33 ± 0.023 0.17 ± 0.017 Muscles 0.10 ± 0.009 0.05 ± 0.006 0.03 ± 0.000 Bones and joints 0.28 ± 0.021 0.10 ± 0.003 0.07 ± 0.009 Brain 0.04 ± 0.003 0.01 ± 0.001 0.01 ± 0.001</p><p>EC, EC, N,N′-ethylene-di-L-cysteine.</p><p>Values are the percentage of injected dose per gram weight ( <em>n</em> = 3) per time interval. Data represent the mean of three measurements ± standard deviation.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="planar-scintigraphic-imaging-study-1"><span class="mr-2">Planar Scintigraphic Imaging Study</span><a href="#planar-scintigraphic-imaging-study-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/4_1s20S1076633212004230.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/4_1s20S1076633212004230.jpg" alt="Figure 5, Planar scintigraphic imaging of 99m Tc-EC ( top ) and 99m Tc-EC-tyrosine ( bottom ) at 30 to 240 minutes in breast tumor–bearing rats. EC, N,N′-ethylene-di-L-cysteine; T, tumor; T/M, tumor/muscle." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="invivo-uptake-blocking-study-1"><span class="mr-2">In Vivo Uptake Blocking Study</span><a href="#invivo-uptake-blocking-study-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/5_1s20S1076633212004230.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/5_1s20S1076633212004230.jpg" alt="Figure 6, (a) Percentage of injected dose (%ID) of selected organs before and after in vivo blocking of 99m Tc-EC-tyrosine by unlabeled L-tyrosine in mammary tumor–bearing rats. (b) Selected organ/muscle ratios before and after in vivo blocking of 99m Tc-EC-tyrosine by unlabeled L-tyrosine in mammary tumor-bearing rats. EC, N,N′-ethylene-di-L-cysteine; K/M, kidney/muscle; L/M, liver/muscle; T/M, tumor/muscle. ∗ P &lt; .05 compared to the control group." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="melphalan-treatment-response-assessment-1"><span class="mr-2">Melphalan Treatment Response Assessment</span><a href="#melphalan-treatment-response-assessment-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/6_1s20S1076633212004230.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/6_1s20S1076633212004230.jpg" alt="Figure 7, (a) Tumor volume change before and after melphalan treatment in 13762 mammary tumor–bearing rats using different doses ( n = 3/dose group). (b) Standard hematoxylin and eosin (H&amp;E) staining and immunohistochemical analysis of L-type amino acid transporter 1 (LAT1) and cellular proliferation marker Ki-67 using 13762 mammary tumor tissue samples before and after treatment with different doses of melphalan. ∗ P &lt; .05 compared to the control group." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/7_1s20S1076633212004230.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/Developmentof99mTcECtyrosineforEarlyDetectionofBreastCancerTumorResponsetotheAnticancerDrugMelphalan/7_1s20S1076633212004230.jpg" alt="Figure 8, Tumor/muscle (T/M) ratios of 99m Tc-EC-tyrosine in breast tumor–bearing rats before and after treatment with different doses of melphalan ( n = 3/dose group) for 1 to 4 hours. EC, N,N′-ethylene-di-L-cysteine. ∗ P &lt; .05 compared to the control group." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="conclusions-1"><span class="mr-2">Conclusions</span><a href="#conclusions-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Rosenbaum S.J., Lind T., Antoch G., et. al.: False-positive FDG PET uptake—the role of PET/CT. Eur Radiol 2006; 16: pp. 1054-1065.</p><li><p>2. Lim H.S., Yoon W., Chung T.W., et. al.: FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics 2007; 27: pp. S197-S213.</p><li><p>3. Aukema T.S., Rutgers E.J., Vogel W.V., et. al.: The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol 2010; 36: pp. 387-392.</p><li><p>4. Jager P.L., Vaalburg W., Pruim J., et. al.: Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42: pp. 432-445.</p><li><p>5. McConathy J., Goodman M.M.: Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. Cancer Metastasis Rev 2008; 27: pp. 555-573.</p><li><p>6. Kole A.C., Nieweg O.E., Pruim J., et. al.: Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET. J Nucl Med 1997; 38: pp. 692-696.</p><li><p>7. Kaira K., Oriuchi N., Imai H., et. al.: Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci 2009; 100: pp. 248-254.</p><li><p>8. Furuya M., Horiguchi J., Nakajima H., et. al.: Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci 2012; 103: pp. 382-389.</p><li><p>9. del Amo E.M., Urtti A., Yliperttula M.: Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 2008; 35: pp. 161-174.</p><li><p>10. Samuels B.L., Bitran J.D.: High-dose intravenous melphalan: a review. J Clin Oncol 1995; 13: pp. 1786-1799.</p><li><p>11. Harada N., Nagasaki A., Hata H., et. al.: Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake. Acta Haematol 2000; 103: pp. 144-151.</p><li><p>12. Moscow J.A., Swanson C.A., Cowan K.H.: Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer 1993; 68: pp. 732-737.</p><li><p>13. Jurisson S., Cutler C., Smith S.V.: Radiometal complexes: characterization and relevant in vitro studies. Q J Nucl Med Mol Imaging 2008; 52: pp. 222-234.</p><li><p>14. Marzilli L.G.: Linking deprotonation and denticity of chelate ligands. Rhenium(V) oxo analogs of technetium-99m radiopharmaceuticals containing N2S2 chelate ligands. Inorg Chem 1994; 33: pp. 4850-4860.</p><li><p>15. Anderson C.J., John C.S., Li Y.J., et. al.: N, N′-ethylene-di-L-cysteine (EC) complexes of Ga(III) and In(III): molecular modeling, thermodynamic stability and in vivo studies. Nucl Med Biol 1995; 22: pp. 165-173.</p><li><p>16. Feldman J.G.R., Mark S., Schwartz J., et. al.: A methematical model for tumor volume evaluation using two-dimensions. J Appl Quan Meth 2009; 4: pp. 8.</p><li><p>17. Kong F.L., Zhang Y., Ali M.S., et. al.: Synthesis of (99m)Tc-EC-AMT as an imaging probe for amino acid transporter systems in breast cancer. Nucl Med Commun 2010; 31: pp. 699-707.</p><li><p>18. Yanagida O., Kanai Y., Chairoungdua A., et. al.: Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001; 1514: pp. 291-302.</p><li><p>19. Shikano N., Kawai K., Nakajima S., et. al.: Renal accumulation and excretion of radioiodinated 3-iodo-alpha-methyl-L-tyrosine. Ann Nucl Med 2004; 18: pp. 263-270.</p><li><p>20. Amano S., Inoue T., Tomiyoshi K., et. al.: In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med 1998; 39: pp. 1424-1427.</p><li><p>21. Bergstrom J., Furst P., Noree L.O., et. al.: Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol 1974; 36: pp. 693-697.</p><li><p>22. Lin J., Raoof D.A., Thomas D.G., et. al.: L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett’s adenocarcinoma. Neoplasia 2004; 6: pp. 74-84.</p><li><p>23. He B., Frey E.C.: Comparison of conventional, model-based quantitative planar, and quantitative SPECT image processing methods for organ activity estimation using In-111 agents. Phys Med Biol 2006; 51: pp. 3967-3981.</p><li><p>24. Pereira J.M., Stabin M.G., Lima F.R., et. al.: Image quantification for radiation dose calculations—limitations and uncertainties. Health Phys 2010; 99: pp. 688-701.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-20/'>Volume 20</a>, <a href='/categories/issue-1/'>Issue 1</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Development%20of99m%20Tc-EC-tyrosine%20for%20Early%20Detection%20of%20Breast%20Cancer%20Tumor%20Response%20to%20the%20Anticancer%20Drug%20Melphalan%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fdevelopment-of99m-tc-ec-tyrosine-for-early-detection-of-breast-cancer-tumor-response-to-the-anticanc%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Development%20of99m%20Tc-EC-tyrosine%20for%20Early%20Detection%20of%20Breast%20Cancer%20Tumor%20Response%20to%20the%20Anticancer%20Drug%20Melphalan%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fdevelopment-of99m-tc-ec-tyrosine-for-early-detection-of-breast-cancer-tumor-response-to-the-anticanc%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fdevelopment-of99m-tc-ec-tyrosine-for-early-detection-of-breast-cancer-tumor-response-to-the-anticanc%2F&text=Development%20of99m%20Tc-EC-tyrosine%20for%20Early%20Detection%20of%20Breast%20Cancer%20Tumor%20Response%20to%20the%20Anticancer%20Drug%20Melphalan%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/after-hours-coverage-of-various-radiologic-subspecialties-and-its-impact-on-the-fourth-year-radiolog/"><div class="card-body"> <em class="small" data-ts="1356973200" data-df="ll" > Dec 31, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>After-hours Coverage of Various Radiologic Subspecialties and Its Impact on the Fourth-year Radiology Residency Curriculum</h3><div class="text-muted small"><p> Rationale and Objective The modification of the initial radiology board exam series has as a concerted aim the promotion of subspecialization. Yet, in practice, fellowship-trained radiologists may...</p></div></div></a></div><div class="card"> <a href="/posts/comparison-of-semi-automatic-volumetric-vx2-hepatic-tumor-segmentation-from-cone-beam-ct-and-multi-d/"><div class="card-body"> <em class="small" data-ts="1356973200" data-df="ll" > Dec 31, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Comparison of Semi-automatic Volumetric VX2 Hepatic Tumor Segmentation from Cone Beam CT and Multi-detector CT with Histology in Rabbit Models</h3><div class="text-muted small"><p> Rationale and Objectives The purpose of this study was to compare tumor volume in a VX2 rabbit model as calculated using semiautomatic tumor segmentation from C-arm cone-beam computed tomography (...</p></div></div></a></div><div class="card"> <a href="/posts/comparison-of-t1-dgemric-and-quantitative-t2-mri-in-preoperative-acl-rupture-patients/"><div class="card-body"> <em class="small" data-ts="1356973200" data-df="ll" > Dec 31, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Comparison of T1ρ, dGEMRIC, and Quantitative T2 MRI in Preoperative ACL Rupture Patients</h3><div class="text-muted small"><p> Rationale and Objectives T1ρ, inversion recovery sequence with a gadolinium contrast agent (dGEMRIC), and T2 mapping have shown sensitivity toward different osteoarthritic-associated compositional...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/comparison-of-t1-dgemric-and-quantitative-t2-mri-in-preoperative-acl-rupture-patients/" class="btn btn-outline-primary" prompt="Older"><p>Comparison of T1ρ, dGEMRIC, and Quantitative T2 MRI in Preoperative ACL Rupture Patients</p></a> <a href="/posts/educating-leaders/" class="btn btn-outline-primary" prompt="Newer"><p>Educating Leaders</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
